EU Court Rejected Novartis Trademark Challenge
The ruling clears the path for competitors to register similar brand names in the European pharmaceutical market.
Updated on Sept. 23, 2026 in Healthcare
Live Poll
Should large companies have stronger legal protections against competitors using similar-sounding brand names?
The EU General Court has ruled against Novartis in a dispute challenging the registration of the Devatis trademark. The decision establishes that the strength of a major pharmaceutical brand does not automatically preclude the entry of similarly named rivals.
Why it matters
This case clarifies the threshold for trademark protection in the European pharmaceutical sector, where brand recognition is a primary competitive asset. Operators should note that the court prioritized distinctiveness over the broad reach of an incumbent's reputation.
The ruling involved a single legal challenge regarding trademark similarities, specifically weighing the claimant's brand reputation against the registrant's identity. The court's decision confirms the current standing of the Devatis brand registration.
The players
Novartis
A multinational pharmaceutical corporation based in Switzerland with a large portfolio of patented and generic drugs.
Devatis
A pharmaceutical company of Turkish origin that successfully defended its right to use its registered trademark.
EU General Court
The judicial body responsible for adjudicating legal disputes concerning trademark registrations and EU competition law.
The details
The EU General Court concluded that the Devatis trademark does not infringe on the rights of the Swiss pharmaceutical giant, Novartis. Judges emphasized that while Novartis holds a significant brand reputation, it failed to demonstrate that the new registration would cause enough consumer confusion to block its use. This decision shifts the burden of proof for pharmaceutical companies seeking to protect their branding from smaller, regional competitors.
Timeline
September 23, 2026: The EU General Court issued the ruling.
Market Landscape
This case follows a pattern set by EU trademark law, where courts increasingly favor specific evidence of market confusion over broad claims of brand fame. It underscores a trend where established giants face higher hurdles when attempting to exclude newer entrants through administrative opposition.
Operators in highly regulated sectors like pharmaceuticals should re-evaluate their brand protection strategy to ensure it relies on concrete evidence of potential consumer confusion. Consult with intellectual property counsel to assess whether current brand defense protocols meet these updated judicial standards.
The takeaway
Incumbent market dominance is not a blanket safeguard for preventing competitor branding in the EU. Businesses should track if their own trademark portfolio relies on legacy reputation rather than distinctiveness that could withstand a court challenge.
Further reading
For more on industry-wide branding and regulatory trends, see the Healthcare section.
Source note: This article includes information reported by Mlex.
Live Poll
Should large companies have stronger legal protections against competitors using similar-sounding brand names?
